Suppr超能文献

新生仔猪急性肺损伤后经支气管肺泡灌洗给予稀释表面活性剂

Lavage administration of dilute surfactants after acute lung injury in neonatal piglets.

作者信息

Balaraman V, Meister J, Ku T L, Sood S L, Tam E, Killeen J, Uyehara C F, Egan E, Easa D

机构信息

Department of Pediatrics, Medicine and Pathology, John A. Burns School of Medicine, University of Hawaii and Kapiolani Medical Center for Women and Children, Honolulu, HI 96826, USA.

出版信息

Am J Respir Crit Care Med. 1998 Jul;158(1):12-7. doi: 10.1164/ajrccm.158.1.9704119.

Abstract

Exogenous surfactant therapy is not standard in the acute respiratory distress syndrome (ARDS) because of a lack of proven benefit. Nonuniform surfactant distribution after either bolus or aerosol administration may be an important factor limiting response. In a previous study of acute lung injury, we demonstrated that lavage administration of Exosurf (13.5 mg phospholipid/ml) was both effective and distributed uniformly in the lungs. Since the endogenous surfactant pool is much smaller than the typical dose of exogenous surfactant administered, we hypothesized that dilute surfactant preparations (4-4.5 mg phospholipid/ml) administered by lung lavage would be equally effective in reversing pulmonary dysfunction in a piglet model of acute lung injury. We compared three dilute surfactants: Infasurf (n = 5), KL4-Surfactant (n = 6), and Exosurf (n = 5) with controls (n = 6) and undiluted Exosurf (13. 5 mg phospholipid/ml; n = 6). All dilute surfactant preparations were effective in improving oxygenation and other parameters of pulmonary function. Surfactant administered by lavage resulted in uniform lung distribution. We conclude that dilute surfactants administered by lung lavage are effective in reversing pulmonary dysfunction after acute lung injury. We speculate that doses in the range of 20-40 mg phospholipid/kg may be adequate to improve lung function in ARDS when exogenously administered surfactant is uniformly distributed in the lung.

摘要

由于缺乏已证实的益处,外源性表面活性剂疗法在急性呼吸窘迫综合征(ARDS)中并非标准治疗方法。推注或雾化给药后表面活性剂分布不均可能是限制疗效的一个重要因素。在先前一项关于急性肺损伤的研究中,我们证明了通过灌洗给予Exosurf(13.5毫克磷脂/毫升)既有效,又能在肺中均匀分布。由于内源性表面活性剂储备比外源性表面活性剂的典型给药剂量小得多,我们推测通过肺灌洗给予稀释的表面活性剂制剂(4 - 4.5毫克磷脂/毫升)在急性肺损伤仔猪模型中逆转肺功能障碍方面同样有效。我们将三种稀释的表面活性剂:固尔苏(n = 5)、KL4 - 表面活性剂(n = 6)和Exosurf(n = 5)与对照组(n = 6)和未稀释的Exosurf(13.5毫克磷脂/毫升;n = 6)进行了比较。所有稀释的表面活性剂制剂在改善氧合和其他肺功能参数方面均有效。通过灌洗给予的表面活性剂在肺中分布均匀。我们得出结论,通过肺灌洗给予稀释的表面活性剂在逆转急性肺损伤后的肺功能障碍方面是有效的。我们推测,当外源性给予的表面活性剂在肺中均匀分布时,20 - 40毫克磷脂/千克范围内的剂量可能足以改善ARDS患者的肺功能。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验